Gyo Asai

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Haruhiro Saito, Tatsuro Fukuhara, Naoki Furuya et al. · The Lancet Oncology · 2019 · 626 citations

Interim Analysis, Oncology, Bevacizumab Versus Erlotinib +8

UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan

Yukio Ando, Hideo Saka, Gyo Asai et al. · Annals of Oncology · 1998 · 205 citations

Reductive Stress, Biosynthesis, Biochemistry +8

Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer.

Nobuyuki Yamamoto, Junji Tsurutani, Naruo Yoshimura et al. · PubMed · 2006 · 75 citations

Refractory Sclc, Oncology, Refractory Cases +14

Influence of histological type, smoking history and chemotherapy on survival after first‐line therapy in patients with advanced non‐small cell lung cancer

Toru Itaya, Nobuyuki Yamaoto, Masahiko Ando et al. · Cancer Science · 2006 · 37 citations · Full text

Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study

Tatsuro Fukuhara, Haruhiro Saito, Naoki Furuya et al. · EBioMedicine · 2020 · 28 citations · Full text